Aarti Drugs Ltd's earnings have grown by 33.3%, whereas share price has appreciated 27% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.
Aarti Drugs Ltd share price has appreciated 48.9% annually (CAGR) over the past ten years.
Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that Aarti Drugs Ltd is a good long term investment. However, you need to ensure you buy at a right price to earn good returns.
Aarti Drugs (ADL), incorporated in 1984, is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries.
ADL manufactures drugs in therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, anti-cholinergic, sedatives, anti-depressant, anti-diarrhea and anti-inflammatory. The companyâ€™s manufacturing facilities are located at Tarapur and Sarigam.
ADL manufactures drugs in therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, anti-cholinergic, sedatives, anti-depressant, anti-diarrhea and anti-inflammatory. The companyâ€™s manufacturing facilities are located at Tarapur and Sarigam. The drug major has received ISO 9001:2000 certifications for quality management.
API- ADL manufactures active pharmaceuticals ingredients (API) and steroids. Under API, it manufactures products such as aceclofenac, clopidogrel bisulphate, ketoconazole, metformin HCl, hydroxyzine pomoate, ketoconazole, irbesartan and many more. The company manufactures steroids such as hydrocortisone sodium succinate sterile, hydrocortisone acetate, hydrocortisone and hemisuccinate.
Pharma Intermediates- The company manufactures pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine
Speciality Chemicals- Under this, the company manufactures products such as benzene sulphonyl chloride, benzene sulphonamide, diphenyl sulphone, N-ethyl toluene sulphonamide, ethyl toluene sulphonate, para chloro benzene sulphonamide, benzene sulfonyl hydrazide and many more.
The companyâ€™s R&D centre at Turbhe near Mumbai, focuses on developing new value added molecules. This facility is recognised by Department of Science and Industrial Research and Government of India.
The company also undertakes contract manufacturing for its customers.
ADL's products are exported to over 85 countries across the globe. It has received Export House Status recognition of from Government of India. The company has clientele namely Sanofi-Aventis, Merck, Teva , Searle, Pfizer, Bayer and Clariant to name a few.
Aarti Drugs' R&D programs are currently focused on new products amongest non-steroidal NSAID compounds, antiparasitic, calciun antagonist, antianginal, antidiabetics, antdepressant and many more. The company has also planned to work on speciality chemicals and agro chemicals.